September 2020 – Seal Biosciences receives Notice of Publication for patent application 16/878,973 entiltled “Prognostic and Diagnostic Methods for Colorectal Cancer”
April 2020 – Seal Biosciences successfully executes limited fundraising round
December 2019 – Roose lab at UCSF generates new RasGRP1 antibodies
August 2019 – JCI Insight publication supporting value of RasGRP1 as prognostic marker
September 2017 – Seal Biosciences successfully executes limited fundraising round
October 2016 – Seal Biosciences signs collaboration agreement with Roose lab
August 2016 – Seal Biosciences signs agreement with European CRC clinicians
March 2016 – UCSF files patent with Seal Biosciences as licensing partner
May 2015 – Seal Biosciences purchases exclusive license
April 2015 – Roose lab (UCSF) files provisional patent